Small molecule (Molecular glue degrader) · Degrader of cereblon (CRBN), Aiolos (IKZF3) and Ikaros (IKZF1) · developed by Bristol Myers Squibb
Iberdomide is a cereblon-modulating protein degrader that binds cereblon, a substrate receptor of an E3 ubiquitin ligase, and promotes ubiquitination and proteasomal degradation of the transcription factors Aiolos and Ikaros. It is studied in multiple myeloma, including refractory disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 13, 2026). Read the full label for the exact wording, limitations and safety information.
Multiple MyelomaMyelomaRefractory Multiple Myeloma
Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.
See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMY catalysts and pipeline →